Few Stick With Ozempic; Pfizer Making Daily GLP-1; Once-Weekly Insulin Turned Down

Only 25% of patients prescribed semaglutide (Ozempic, Wegovy) for weight loss were still on it 2 years later, according to an analysis of U.S. pharmacy claims data by Prime Therapeutics and Magellan Rx Management.

A study in older patients with type 2 diabetes found no clear increased risk of suicidal ideation with use of GLP-1 receptor agonists. (Annals of Internal Medicine)

Pfizer said it’s developing a once-daily GLP-1 weight loss pill.

In postmenopausal women with osteoporosis, romosozumab (Evenity) yielded larger increases in bone mineral density after 12 months compared with teriparatide and with lower discontinuation rates. (Journal of Clinical Endocrinology & Metabolism)

Novo Nordisk said the FDA declined to approve its once-weekly insulin for diabetes after a negative advisory committee review.

Meanwhile, the company faces scrutiny on Capitol Hill after withdrawing its long-acting insulin (Levemir) from the U.S. market. (Reuters)

Authors of a JAMA Internal Medicine viewpoint said Switzerland has an overall higher per-capita uptake of GLP-1 agents for weight loss. The drugs are reimbursed there, but the country has negotiated lower prices and applies stricter prerequisites for administration and monitoring. The authors argue that such a system may make GLP-1 drugs more affordable and reduce off-label use and shortages.

Members of an Australian religious group are on trial after being accused of killing an 8-year-old girl with diabetes by denying her medical care and offering prayer instead. (BBC)

People exposed to brighter night light and light patterns that may disrupt circadian rhythms had a higher risk of type 2 diabetes. (Lancet Regional Health Europe)

Could a hormone released by the brains of lactating mice hold promise as an osteoporosis treatment? (Science)

Meet trifluoroacetic acid or TFA: another “forever chemical” in drinking water that may be more prevalent than previously thought. (Washington Post)

Please enable JavaScript to view the

comments powered by Disqus.